Stockscreener 앱 받기
8.96
1.86%
-0.17
시간 외 거래:
8.96
전일 마감가:
$9.13
열려 있는:
$9.02
하루 거래량:
467.41K
Relative Volume:
0.47
시가총액:
$451.48M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.7034
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+9.80%
1개월 성능:
+4.92%
6개월 성능:
+13.71%
1년 성능:
-37.73%
1일 변동 폭
$8.86
$9.22
1주일 범위
$8.14
$9.22
52주 변동 폭
$5.035
$15.36
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.96 | 460.05M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
What is the dividend policy of REGENXBIO Inc. stockInvest confidently with professional guidance - jammulinksnews.com
What are the latest earnings results for REGENXBIO Inc.Invest smarter with expert stock picks - jammulinksnews.com
What catalysts could drive REGENXBIO Inc. stock higher in 2025Free Popular Stock Recommendations - jammulinksnews.com
What drives REGENXBIO Inc. stock priceJaw-dropping returns - PrintWeekIndia
What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com
REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey
What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional
The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com
REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com
REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance
(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News
Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com
RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - MarketScreener
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive
RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter
REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa
Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech
New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com
Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Regenxbio Inc 주식 (RGNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
0.97%
0.22%
자본화:
|
볼륨(24시간):